All News

Article

GLP-1 Agonists Show Promise in Slowing Kidney Disease in Lupus Nephritis

Bella Mehta, MBBS, MS Nov 18, 2024

A retrospective cohort study presented at #ACR24 explores the benefits of GLP-1Ras in reducing the risk of end-stage renal disease (ESRD) for patients with lupus nephritis. Drawing on data from the TrinetX global research database, the study examines how GLP-1Ras may reduce ESRD progression in a population where 10-20% progress to ESRD within five years, even with immunosuppressive therapies.

A call to action in diagnosing and treating NPSLE 👇 Wonderful talks by Dr @ZahiTouma Dr. Betty Diamond and Dr. Susanne Benseler @Rheumnow #ACR24 #lupus https://t.co/046ArRMP1a

https://x.com/RHEUMarampa/status/1858605373986623942/photo/1

Medeiros-Ribeiro et al. Holding MTX for 2 weeks after recombinant zoster vaccine increases response with no increase in flare. @RheumNow #ACR24 Abstr#2612 https://t.co/NEop0XB5Ak https://t.co/P4S2qzbkTs

SmPCs recommend interrupting immunosuppression (IS) in infection What happens if you continue the drug? Ab2611 found no difference in infection outcomes btwn temp interruption & continuation of IS in infection Could continuation be a safe option in some pts? #ACR24 @RheumNow https://t.co/14SN6a4Wm8

https://x.com/DrMiniDey/status/1858606604293468406/photo/1

RIP to Glucocorticoids in GPA For many years glucocorticoids were the mainstay of our treatment of granulomatosis with polyangiitis (GPA). https://t.co/WqpO6ACqtu https://t.co/vb8qx3uHA0

RIP to Glucocorticoids in GPA | RheumNow

Evaluation of Bimekizumab in PsA At last year’s ACR, I shared about the early clinical trial data on bimekizumab in psoriatic arthritis. Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2… https://t.co/lphZUiiq5T https://t.co/zuHpBaMtEv

RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis.All content is chosen by RheumNow & its faculty

Study on #SLE and ESRD using machine learning: Developed model to identify patients with SLE and ESRD Used NIH 'All of Us' dataset XGBoost outperformed Random Forest SDOH data improved model precision #ACR24 @rheumnow #MachineLearning abst#1876 https://t.co/PQ7u4Pj5OH

https://x.com/bella_mehta/status/1858566338844799022/photo/1

Wang et al. Propensity score matched cohort study. 63,302 individuals. Colchicine associated lower risk of THR/TKR, HR 0.87. @RheumNow #ACR24 Abstr#2557 https://t.co/UUU3Tm67ML https://t.co/uKi0e8E7HV

@RheumNow interview at #ACR24 with Dr Harry Hurley about A#1694 Should we do one or two lungs when transplanting for autoimmune related ILD? https://t.co/2omSSAPvgi https://t.co/BlAQjuBRFt

Zou et al. Phase 2 RCT Vunakizumab, humanized IL17A in PsA. 12 week study. ACR responses shown in figure, looks similar to existing IL17As. @RheumNow #ACR24 Abstr#2581 https://t.co/Td5xlMYrAd https://t.co/Rl4gkmDFOR

How Online Searches Reveal Patient Needs In the digital age, managing health conditions is rapidly evolving as patients increasingly turn to online resources for answers—over 65% search for health-related questions online. #ACR24 https://t.co/AbHGNAsIpH https://t.co/nuoQeigJfE

How Online Searches Reveal Patient Needs | RheumNow

A#2363 Deodhar Bimekizumab fast time to work: BE MOBILE 1 and 2 - rapid treatment responses with separation from PBO as early as 1-2 weeks after single dose. @RheumNow #ACR24 https://t.co/T81Lzyoy7m

https://x.com/ericdeinmd/status/1858556716075339953/photo/1

Xia et al. Upadacitinib in refractory Behcets. Open label, 8 patients. Follow-up 4-14 months. Lower disease activity 2.5 vs 1.5. Lower pred, 11.9 vs 8.1. @RheumNow #ACR24 Abstr#2515 https://t.co/ZXsJkNRlTm https://t.co/S8LhpqZ8X3

Disease specific chatbots might be primetime - investigators from NYC made the a #LupusCoach chatbot - patients indicated high levels of satisfaction and were excited about it. @rheumnow abst#2160 #ACR24

In the horizon for Knee #OA pain management - XG005 - non opioid inhibiting inflammatory and neuropathic signals via the COX enzymes and the calcium subunit. Phase 2b , placebo control, double blind study Abst #L08 #ACR24 @RheumNow https://t.co/j4qkj1Xvbr

https://x.com/bella_mehta/status/1858558034366304734/photo/1

Reproductive Issues in axSpA: Fertility and Pregnancy axSpA affects young patients with symptom onset occurring in early adulthood. Apart from pain and quality of life, reproductive issues also arise because patients who are diagnosed with the disease are also in their… https://t.co/8tLFOvFqdO https://t.co/E3AOOCHTgu

Ahmadzay et al. Real world secukinumab in PsA data in 1202 patients. Smokers/ex-smokers have 30% lower treatment retention. But if they maintain treatment, appear to respond equally well. BMI no effect. @RheumNow #ACR24 Abstr#2350 https://t.co/XVPmEBbRu8 https://t.co/QyJirWRKvq

A#2291 ESSDAI does not correlate to PROMISE (pt outcomes) in Sjogrens Symptomatology is complex in SjD and beyond traditional disease activity markers @RheumNow #ACR24 https://t.co/AhstAFjOVS

https://x.com/ericdeinmd/status/1858553904314667181/photo/1

Abstract 1873: The impact of urbanization on lupus nephritis mortality is complex. Race/ethnicity + income modify the effects - Income ≥$50k + living in suburbs associated with lower odds of mortality due to LN in racial/ethnic minorities @RheumNow #ACR24

Topics

All News

GLP-1 Agonists Show Promise in Slowing Kidney Disease in Lupus Nephritis

Do you get our email newsletter?